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Background: To determine occurrence of features of intraoperative ﬂ  oppy iris syndrome (IFIS) 
during cataract surgery in patients taking systemic alpha-antagonists (AA).
Methods: We prospectively studied patients on AA and who underwent phacoemulsiﬁ  cation. 
The following were recorded: pupil diameter preoperatively, iris ﬂ  accidity, iris prolapse and 
peroperative miosis.
Results: We studied 40 eyes of 31 subjects. Mean age was 78 years. Overall, 14 eyes (13 patients) 
showed signs of IFIS: 9/13 (69%) eyes of patients on tamsulosin, 1/18 (6%) eyes in the doxazosin 
group, 2/2 prazosin patients, 1/4 eyes in the indoramin group, and 1/2 eyes in two patients on a 
combination of doxazosin and tamsulosin. Most cases (92%) had only one or two signs of IFIS. 
Bilateral cataract surgery was undertaken in 9 patients but only one patient (on tamsulosin) had 
features of IFIS in both eyes, while 4 patients (2 on tamsulosin and 2 on other AA) showed 
signs of IFIS in one eye only, and 4 patients did not show IFIS in either eye.
Conclusion: Most AA were associated with IFIS, but it tends to present as a spectrum of signs 
rather than full triad originally described. Tamsulosin was most likely to be associated with 
IFIS; however, its intake does not necessarily mean that IFIS will occur. For patients on AA, 
the behavior of the iris intraoperatively in one eye is a poor predictor of the other eye. Surgeons 
should anticipate the occurrence of IFIS in any patient on AA.
Keywords: alpha blocker, alpha antagonist, cataract surgery, intraoperative ﬂ  oppy iris syndrome, 
tamsulosin.
Introduction
Chang and Campbell (2005a) were the ﬁ  rst to describe the intraoperative ﬂ  oppy iris 
syndrome (IFIS) which is characterized by the triad of: a ﬂ  accid iris stroma that undu-
lates and billows in response to ordinary intraocular ﬂ  uid currents, a propensity for 
the ﬂ  oppy stroma to prolapse towards the phaco and side-port incisions despite proper 
wound construction, and progressive intraoperative pupil constriction despite standard 
preoperative pharmacologic measures designed to prevent this. They, and later other 
authors, found a strong association between IFIS and systemic use of tamsulosin, a 
selective α1A and α1D adrenergic receptor antagonist (AA) (Parssinen 2005).
Schwinn and Afshari (2005a) later suggested that IFIS can be associated with 
other commercially available nonselective AA. Some case reports have implicated 
the use of alfuzosin and doxazosin with IFIS (Chang and Campbell 2005b; Settas and 
Fitt 2006). However, a recent study has reported that nonselective AA are unlikely 
to be associated with IFIS (Chadha et al 2007). In this prospective descriptive study, 
we aim to determine the occurrence of the features of IFIS during cataract surgery in 
patients taking all types of AA.
Methods
This is a prospective descriptive case series. Patients were enrolled at preoperative 
assessment for cataract surgery at a large university hospital ophthalmology department. Clinical Ophthalmology 2008:2(4) 736
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Inclusion criteria were patients on alpha-blockers. Exclusion 
criteria were previous ocular trauma, surgery or pseudoexfo-
liation. Surgery was carried under the care of 6 consultants 
between March and October 2006. A standard pupil dilation 
regimen of 1 drop of cyclopentolate 1% and phenylephrine 
2.5% was used. Pupil diameters pre and post-dilation were 
measured by two observers (OH and SI) using a pupil gauge, 
in the same lighting conditions (mesopic). All patients under-
went phacoemulsiﬁ  cation. The surgeon was not masked to 
the type of AA the patient was using. A standard question-
naire (Figure 1) was ﬁ  lled in by the surgeon after the surgery. 
Data was recorded from this questionnaire and by review 
of hospital notes. All methods have followed the Tenets of 
the Declaration of Helsinki. Patients continued taking their 
regular AA medications as usual before the surgery.
Demographics and AA used were recorded. Outcome 
variables were pre- and post-dilation pupil size, and intra-
operative evidence of IFIS (iris flaccidity, tendency of 
iris to prolapse and miosis during surgery). Peroperative 
complication rates were also recorded.
Data were stored and analyzed by Excel (2000; Microsoft 
Corporation, Redmond, WA). Differences between numeri-
cal data for pupil size were assessed by the unpaired Student 
two-tailed t-test. A P-value of less than 0.05 was considered 
statistically signiﬁ  cant.
Results
Thirty-one patients (40 eyes) were included in this study. 
Mean age (± standard deviation [SD]) was 78 (±7.4), and 
58% were male and 42% were female. Only one patient was 
Asian and the rest were Caucasian.
Table 1 shows the use of alpha-blockers in these patients.
Pupil diameter
Pupil diameter means are shown in Table 2. There was no 
signiﬁ  cant difference between the pre- and postdilation 
pupil sizes in the two groups (tamsulosin and nontamsulosin 
groups) (Table 2). There was no signiﬁ  cant difference 
between diabetic and nondiabetic patients. However, the 
method used to measure pupil diameter in this study has 
To be completed by surgeon.
Please answer these questions after the cataract surgery:
Date of surgery:………………… Right/ Left Phaco
1. Iris hooks used? Yes/No
2. Other techniques used to dilate pupil?
    (eg, stretching / Healon-GV/ etc.)                                           Yes/No 
 Please Specify:…………………………………………………….
3. Flaccid iris that undulates and billows in response
    to intraocular fluid currents during
    hydrodissection/ phaco/ I&A?     Yes/No
4. Iris prolapse towards phaco or side-port incisions?   Yes/No
5. Progressive intraoperative pupil constriction?   Yes/No
6. Other comments:…………………………..…………………….......
…………………………………………………………………………….
Figure 1 Alpha-blockers and intraoperative ﬂ  oppy iris syndrome surgeon questionnaire.Clinical Ophthalmology 2008:2(4) 737
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signiﬁ  cant intra- and interobserver variability and this 
limits the reliability of our values. Furthermore, a larger 
number of patients are required to detect a statistically 
significant difference between pupil diameters in the 
two groups.
IFIS
Overall, 13 patients (14 eyes) showed some signs consistent 
with IFIS (Table 3) and (Figure 2). The majority of these 
patients (9 patients (10 eyes)) were on tamsulosin. The most 
frequent sign of IFIS was iris ﬂ  accidity; 11 of 14 cases, fol-
lowed by iris prolapse 7 of 14 cases. In many cases intraop-
erative miosis was difﬁ  cult to comment on as intraoperative 
intervention was used.
Tamsulosin
In the tamsulosin group (13 eyes), 9 eyes (69%) showed at 
least one of the signs of IFIS (Table 3). The majority (7 eyes) 
showed only one of the signs of IFIS and two eyes showed 
2 signs. None of the tamsulosin eyes showed the full-blown 
syndrome (although iris intervention was used in several 
cases which would prevent all the signs of IFIS becoming 
manifest). Eight eyes in this group (62%) had some intra-
operative intervention to minimize the effect of IFIS. Iris 
hooks were used in 6 eyes and intracameral phenylephrine 
was used in 2 (including one patient as a precaution, who 
showed no signs of IFIS.
Nontamsulosin AA
In the doxazosin group (18 eyes), only 1 eye (6%) dem-
onstrated the IFIS triad. The rest of the irides behaved 
normally intra-operatively. Interestingly, the two patients, 
who were taking prazosin, showed signs of IFIS and one 
of them needed intracameral phenylephrine to stabilize 
the iris. Only 1 eye (25 %) in the indoramin group showed 
signs of IFIS that required insertion of iris hooks to 
minimize iris billowing. The only patient with a history 
of alfuzosin use in this series showed normal iris behavior 
intraoperatively.
Effect of simultaneous use
of two alpha-blockers
Two patients were on both tamsulosin and doxazosin. One 
eye of one of these patients showed signs of IFIS.
Bilaterality of IFIS
Bilateral cataract surgery was undertaken in 9 patients (18 
eyes) in this series. Only one patient showed signs of IFIS in 
both eyes and that patient was on tamsulosin. Four patients 
(62%) showed signs of IFIS in one eye only (2 on tamsulo-
sin, 1 on doxazosin, and 1 on indoramin). Four patients did 
not show signs of IFIS in either eye (1 on tamsulosin, 2 on 
doxazosin, and 1 on indoramin) (Table 4).
Gender
Most patients who showed features of IFIS were male (92%). 
Only one female showed signs of IFIS (indoramin). All 
Table 1 Alpha blocker treatment, indication, dosage, afﬁ  nity to alpha receptor subtypes and gender
Medication Number of patients 
(Number of eyes)
Male Female Indication for 
treatment
Daily dose Relative afﬁ  nity to 
α-receptor subtype
Doxazosin 15(18) 3 12 HTN 4–8 mg α1A = α1B = α1D
Tamsulosin 9 (13) 9 0 BPH 0.4 mg α1A = α1D > α1B
Indoramin 2 (4) 1 1 HTN 100 mg α1A = α1B = α1D
Prazosin 2 (2) 2 0 HTN 5–10 mg α1A = α1B = α1D
Alfuzosin 1 (1) 1 0 BPH 7.5 mg α1A = α1B = α1D
Combination 
(Tamsulosin+ 
Doxazosin)
2 (2) 2 0 HTN + BPH As above
Total 31 (40) 18 13
Abbreviations: BPH, benign prostatic hyperplasia; HTN, hypertension.
Table 2 Mean pupil diameter (in millimeters) before and after 
dilation with cyclopentolate 1% and phenylephrine 2.5%
Predilation 
Right eye
Predilation 
Left eye
Postdilation 
Right eye
Postdilation 
Left eye
Tamsulosin 
group
3.6 (±1.3) 3.5 (±1.3) 7.8 (±1.1) 7.3 (±0.9)
Nontamsu-
losin group
3.5 (±0.6) 3.6 (±0.6) 7.1 (±0.9) 7.2 (±1.5)
P-value 0.655 0.915 0.095 0.692Clinical Ophthalmology 2008:2(4) 738
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Table 3 Patients who had features of intraoperative ﬂ  oppy iris syndrome
Age Sex Alpha-
antagonist
DM Iris ﬂ  accid Iris prolapse Intraoperative miosis Intraoperative
intervention
83 M Doxazosin N Y Y Y Nil
90 F Indoramin N Y N Intraoperative 
intervention used
Iris Hooks
82 M Prazosin Y Y N N Nil
87 M Prazosin N Y N Intraoperative 
intervention used
Intracameral Phenylphrine
73 M Tamsulosin N Y N Intraoperative
 intervention used
Iris Hooks
75 M Tamsulosin N Y N Intraoperative
 intervention used
Iris Hooks
88 M Tamsulosin N N Y Intraoperative 
intervention used
Iris Hooks
74 M Tamsulosin N Y N Intraoperative 
intervention used
Iris Hooks
87 M Tamsulosin N Y Y N Nil
73 M Tamsulosin N N Y N Nil
73 M Tamsulosin N N Y N Nil
77 M Tamsulosin N Y N Intraoperative 
intervention used
Iris Hooks
85 M Tamsulosin N Y Y Intraoperative 
intervention used
Intracameral Phenylphrine
70 M Tamsulosin+ 
doxazosin
Y Y Y Y Nil
Abbreviations: DM, Diabetes Mellitus; Y, yes; N, no.
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Figure 2 Incidence of intraoperative ﬂ  oppy iris syndrome (IFIS) with different alpha antagonists.Clinical Ophthalmology 2008:2(4) 739
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female patients were on doxazosin, except one who took 
indoramin (Table 1).
Diabetes mellitus
Two out of 13 (15%) patients with features of IFIS (one on pra-
zosin and the other on combination of doxazosin and tamsulo-
sin) had diabetes mellitus compared to 2/19 (10.5%) patients 
in the non-IFIS group. However, the number of subjects was 
too small to perform any meaningful statistical test.
Intraoperative complications
No signiﬁ  cant complications were documented in our series.
Discussion
Our study conﬁ  rms the association between tamsulosin and 
IFIS as was initially described (Chang and Campbell 2005a). 
Sixty-nine percent of eyes of patients on tamsulosin showed 
signs of IFIS which is similar to the incidence of 57% quoted 
by Chadha and colleagues (2007) but signiﬁ  cantly less than 
the 100% risk quoted by Chang and Campbell (2005a) in 
their prospective study. The fact that 31% of eyes did not 
demonstrate any features of IFIS means that other cofactors 
(eg, physiological response to AA, pharmacodynamics, 
pharmacokinetics, systemic or ocular pathology) may play 
role in which patients get IFIS. IFIS cases could have been 
under-reported because of use of prophylactic intraoperative 
measures, short exposure to AA and different threshold of 
reporting IFIS by different surgeons. However, the rate of 
IFIS incidence in our study is similar to Chang’s larger study, 
in which surgeons also were allowed to use intraoperative 
prophylactic measures.
Two recent studies have studied the effect of AA on 
pupil diameter. The ﬁ  rst study showed that AA (alfuzosin, 
doxazosin, naftopidil, prazosin, tamsulosin, and terazosin) 
can inhibit the mydriatic effect of phenylephrine, in vivo in 
rabbits (Michel et al 2006). Moreover, this study showed 
that this inhibition can be achieved with AA doses very 
similar to those required to produce their desired therapeutic 
effect on lowering the intraurethral pressure. Also in rabbits 
that did not receive phenylephrine, all AA induced miosis 
at considerably higher doses but tamsulosin was more potent 
than the others which could be attributed to its afﬁ  nity to α1A 
receptors. The second study looked at the effect of tamsulo-
sin and alfuzosin effect on pupil diameter in humans. Pupil 
diameter decreased under mesopic and scotopic light after 
treatment with tamsulosin, but only scotopic pupil diameter 
decreased after treatment with alfuzosin (Altan-Yaycioglu 
2007). Both drugs had no signiﬁ  cant effect on dilated pupil 
measurements. In our study, there was no signiﬁ  cant differ-
ence in the mesopic and dilated pupil diameter between the 
two groups (tamsulosin and other AA groups).
The association between IFIS and other commercially 
available AA (alfuzosin, doxazosin, indoramin, prazosin, and 
terazosin) is less clear due to the fact that these medications, 
with the exception of doxazosin, are less commonly used in 
clinical practice. There is one case report (Muqit and Menage 
2006) and one case series (Chadha et al 2007) describing the 
association of IFIS with doxazosin. In our series, 4 out of 25 
patients taking AA other than tamsulosin had features of IFIS. 
To our knowledge, this is the ﬁ  rst study to show any associa-
tion between IFIS and prazosin or indoramin. The numbers 
are small but may indicate a difference in the incidence of 
IFIS with different AA: both of the patients on prazosin had 
features of IFIS yet only one of 18 patients on doxazosin and 
one eye of two patients on indoramin had signs consistent 
with IFIS. The only patient on alfuzosin had stopped the 
drug a few months previously and did not have signs of IFIS. 
We did not have any patients on terazosin; however, in the 
Chadha and colleagues (2007) series there was one patient 
on this AA but they did not have IFIS.
Diabetes mellitus was slightly more prevalent in the IFIS 
group but we cannot comment on statistical signiﬁ  cance due 
to the small numbers involved. Chadha and colleagues (2007) 
reported no evidence that diabetes contributes to features of 
IFIS although it was associated with small pupil. However, 
we did not ﬁ  nd a signiﬁ  cant difference in pupil size after 
dilation between diabetic and nondiabetic patients probably 
due to the small number of diabetic subjects.
There may be an important element of individual sus-
ceptibility to IFIS but is the occurrence of this syndrome 
consistent between eyes in any given individual? Interest-
ingly, this does not seem to be the case. Of the four patients 
on tamsulosin undergoing bilateral cataract surgery, only 
one had IFIS in both eyes and two had IFIS in only one eye. 
Similarly, of the ﬁ  ve patients on other alpha-blockers who 
underwent bilateral cataract surgery, the two who showed 
Table 4 Occurrence of intraoperative ﬂ  oppy iris syndrome (IFIS) 
in patients who had bilateral cataract surgery.
Medications Bilateral 
IFIS
Unilateral 
IFIS
No signs of 
IFIS
Total 
number of 
patients
Tamsulosin 1 2 1 4
Doxazosin 0 1 2 3
Indoramin 0 1 1 2
Total 1 4 4 9Clinical Ophthalmology 2008:2(4) 740
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features of IFIS had it in one eye only. This different behavior 
in the two eyes of the same patient has also been reported 
by other authors including Schwinn and Afshari (Manvikar 
and Allen 2006; Schwinn and Afshari 2006). It is difﬁ  cult 
to explain given that individual susceptibility, drug kinetics, 
and drug dose would have been expected to be similar for 
both eyes. However, there could have been different surgical 
wound construction techniques and ﬂ  uid ﬂ  ow mechanics 
since different surgeons have been involved and this could 
explain, in part, IFIS predisposition as a local event (Schwinn 
and Afshari 2006). Of the four patients who had bilateral 
cataract surgery and unilateral IFIS, 2 showed signs of IFIS 
in the ﬁ  rst eye and 2 in the second. In all 4, the fellow eye 
showed no features of IFIS during surgery and required no 
prophylactic measures. These ﬁ  ndings suggest that surgeons 
should be aware of the possible occurrence of IFIS in second 
eye surgery of patients on all types of AA even if there were 
no IFIS features in the ﬁ  rst eye.
It is also of interest that only one of the two patients on 
combined tamsulosin and doxazosin treatment showed fea-
tures of IFIS. There have been no previous reports regarding 
the occurrence of IFIS in patients receiving combinations 
of AA. However, the numbers are too small to reach any 
conclusion.
Some authors have suggested stopping AA before elective 
cataract surgery to reduce the risk of complications due to 
IFIS (Manvikar and Allen 2006; Schwinn and Afshari 2006). 
A recent survey reported that 68% of consultants in the UK 
had patients discontinue tamsulosin preoperatively, but they 
found no consistent beneﬁ  t from this protocol (Nguyen 2007). 
In our series, all patients continued their AA treatment and 
there were no intraoperative complications. This is most 
likely due to the use of intraoperative measures (eg, iris hooks 
and intracameral phenylephrine) to limit the effect of IFIS 
features which is in agreement with other authors (Manvikar 
and Allen 2006; Nguyen 2007). Intraoperative prophylactic 
measures in our study were performed at the beginning of 
surgery which could have inﬂ  uenced the number of reported 
IFIS cases and their severity. However, in 8 of 14 eyes which 
developed IFIS, prophylactic measures were used but iris ﬂ  ac-
cidity and prolapse were still observed in some of these cases 
to make diagnosis of IFIS possible. Intraoperative measures 
were used only in 4 of 26 eyes which did not have IFIS.
The major limitations in our study include the factor 
that a number of different surgeons were involved who may 
have had different thresholds for diagnosing the features of 
IFIS. However, the fact that our IFIS incidence in the tamsu-
losin group is similar to the incidence quoted in the literature 
suggests that we were diagnosing IFIS appropriately. Also, 
surgeons were allowed to use intraoperative prophylactic 
measures against IFIS which could have led to masking of 
IFIS signs in some patients. Again, however, the fact that 
our IFIS incidence in the tamsulosin group is similar to the 
literature suggests that this was not a problem. Another 
limitation was that the surgeon was not masked to the type 
of AA. This could have resulted in detection bias in the non-
tamsulosin group because of a lower threshold for reporting 
IFIS in association with AA other than tamsulosin.
Other confounding factors can inﬂ  uence the occurrence 
of IFIS such as the duration of AA therapy. The preoperative 
questionnaire was taken at least four weeks before surgery. 
The actual duration of therapy was not included in our 
questionnaire. However, the actual minimum duration of 
exposure to AA that is required to cause IFIS is not known 
yet. This may explain the fact that not all patients on an AA 
developed IFIS. However, a recent report found that IFIS 
can happen after 2 weeks of starting tamsulosin treatment 
(Chang et al 2007). Finally, co-existing systemic illnesses 
other than diabetes (eg, cardiovascular diseases, autonomic 
nervous dysfunction) and other systemic medications that 
could have some side effects on iris behavior can inﬂ  uence 
IFIS presentation.
In conclusion, the trends suggest that a larger study into 
the incidence of IFIS in patients on alpha-blockers other than 
tamsulosin and doxazosin is warranted. In the meantime, all 
surgeons should be aware of the possible occurrence of IFIS 
in one of both eyes of any patient on AA.
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